我要投票 隆顺榕在中草药行业中的票数:204
· 外 推 电 报 ·
2025-04-21 06:33:40 星期一

【隆顺榕是哪个国家的品牌?】

隆顺榕是什么牌子?「隆顺榕」是 天津中新药业集团股份有限公司 旗下著名品牌。该品牌发源于天津,由创始人李立群在1981-12-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力隆顺榕品牌出海!通过在本页面挂载隆顺榕品牌的产品链接和联系邮箱,可以提高隆顺榕产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中新药业天津隆顺榕制药厂前身是创办于1833年的天津隆顺榕药局,至今己有170余年的发展历史。隆顺榕药局因其品佳质优,经营有术,声誉卓著而成"卫"药魁首。1957年隆顺榕与乐仁堂提炼部合并组建成中药提取制剂的专业生产厂家,即中新药业天津隆顺榕制药厂。中新药业天津隆顺榕制药厂在继承优良传统的基础上,不断创新,其产品以"选材地道、配制精良、工艺先进、疗效确切、功效卓著"而深孚众望、驰名中外,远销港、澳、台、新马等地,曾经是天津市中成药出口基地,全国21家重点中成药生产企业之一。

中新药业天津隆顺榕制药厂多年来一直致力于中药剂型改革的探索和中药技术的研究,是中国中药现代化的发源地。在科研开发、质量管理、生产经营、人才引用等方面都开创了中药制药史的先河:它于1952年在全国首家成立中成药研究机构及全国第一个中药提炼部,并引进了中药界有史以来的第一位留洋博士将传统的中医药理论与现代制剂技术相结合进行中药剂型改革的研究,研制出了第一个中成药片剂-银翘解毒片;第一个中成药酊剂-藿香正气水;第一个中药颗粒剂-当归四逆汤;第一个中药针剂-穿心莲等多种中药新剂型。

在软件建设方面:中新药业天津隆顺榕制药厂是天津首家在生产质量管理中推行全品种标准作业书规范化生产的中成药生产企业,形成了中国中药制药企业的GMP最早的软件雏型。

目前中新药业天津隆顺榕制药厂拥有液剂、片剂、颗粒剂三条生产线,88个注册品种。许多品种曾多次获奖,其中精制银翘解毒片自1958年就开始出口14个国家及地区,一直延续至今,多次荣获天津市优质产品称号;藿香正气水1979年荣获国家银质奖,在以后历届全国同类品种评比中都获得第一。小儿金丹片荣获1983年、1990年《中国妇女儿童用品四十年》博览会金奖。近年来又开发研制出了一系列新品:治疗糖尿病的纯中药制剂金芪降糖片,治疗泌尿系统感染的医院急诊必备中成药癃清片,达到美国FDA新药研究水平的中药复方抗癌药紫龙金片。

中新药业天津隆顺榕制药厂在新的发展形势下确立了"做中药精品创国粹名牌"的企业生存理念,在诚信的基础上推崇以"创新"为核心的企业文化。在销售工作中倡导"诚信经营"的理念;在生产工作中倡导"质量至上"的理念;在技术工作中倡导"创新发展"的理念;在人力资源管理工作中倡导"以人为本"的理念。在过去的三年中,企业已初步成为天津市同行业的排头企业。

企业在发展规划中提出:倡导以“创新”为核心的企业文化,追求卓越,实现企业价值最大化;提供优质产品和服务,为人类创造健康,为社会创造财富;对员工负责满足员工生活和成长需要,使其物质利益和精神利益得以实现;投身社会公益事业,做富有爱心的企业,体现企业的社会价值;传承卫药文化,打造“隆顺榕”强势品牌的指导思想和建立以市场为导向的内部管理机制,重点培养紫龙金片、金芪降糖片的技术含量,为紫龙金片冲击中药抗癌药前三甲,金芪降糖片冲击中药降糖药第一品牌奠定基础;确保员工平均收入年增长幅度不低于8%,人均年累计培训时间不低于96课时;建立合理的人才结构,为企业发展提供人力资本保证;实施差异化发展策略,打造“人无我有,人有我优”的企业核心竞争力;力争将隆顺榕打造成为中国中药行业驰名企业的总体发展目标。

企业决策层认为:曾经引领中国中药工业革命、一度代表天津乃至全国中药工业水平、在中国制药史上留下那么多可圈可点篇章的隆顺榕正面临再次腾飞的历史机遇。拥有紫龙金、金芪降糖片等优秀产品,拥有众多想干事、能干事的员工,背靠着各级领导对企业巨大的政策支持,依托着一百多年来的文化积淀,蕴藏着企业不断创新的动力源泉。不断在继承的基础上进步和发展,这正是隆顺榕的优势所在。

传承百年的隆顺榕,基奠隆顺榕的未来,是历史赋予每个隆顺榕人的重要使命。要站在振兴国粹、推动隆顺榕走向世界的高度上,站在济世寿人、泽及四方、靠企业优秀品质赢取天下人心的境界上,把握明天、决胜今天!未来的隆顺榕一定会更加壮丽!

英文翻译:China new pharmaceutical Tianjin longshunrong pharmaceutical factory was founded in 1833 by Tianjin longshunrong pharmaceutical Bureau. It has a history of 170 years. Longshunrong pharmaceutical Bureau has become the leader of "Wei" medicine for its excellent quality, skillful operation and outstanding reputation. In 1957, longshunrong and lerentang refining department were combined to form a professional manufacturer of Chinese medicine extraction preparations, namely Tianjin longshunrong pharmaceutical factory of China new pharmaceutical industry. Tianjin longshunrong pharmaceutical factory of China New Pharmaceutical Co., Ltd. keeps innovating on the basis of inheriting the fine tradition. Its products are well-known at home and abroad with "authentic material selection, excellent preparation, advanced technology, exact curative effect and outstanding effect". They are exported to Hong Kong, Macao, Taiwan, Xinma and other places. They used to be the export base of Tianjin Chinese patent medicine and one of the 21 key Chinese patent medicine manufacturers in China. Tianjin longshunrong pharmaceutical factory of China New Pharmaceutical Co., Ltd. has been committed to the exploration of traditional Chinese medicine dosage form reform and the research of traditional Chinese medicine technology for many years, which is the birthplace of the modernization of traditional Chinese medicine in China. In scientific research and development, quality management, production and operation, talent introduction and other aspects, it has pioneered the history of traditional Chinese medicine: it was the first to establish a Research Institute of Chinese patent medicine and the first Chinese medicine refining department in 1952 in China, and introduced the first overseas Chinese scholar in the history of traditional Chinese medicine to combine traditional Chinese medicine theory with modern preparation technology for the research of Chinese medicine dosage form reform, The first Chinese medicine tablet Yinqiao Jiedu tablet, the first Chinese medicine tincture Huoxiang Zhengqi water, the first Chinese medicine granule Danggui Sini Decoction, the first Chinese medicine injection Andrographis paniculata and other new Chinese medicine dosage forms have been developed. In terms of software construction: Tianjin longshunrong Pharmaceutical Co., Ltd. of China new pharmaceutical industry is the first Chinese patent medicine manufacturer in Tianjin to carry out standardized production of full variety standard operation manual in production quality management, forming the earliest software prototype of GMP for Chinese traditional medicine pharmaceutical enterprises. At present, China new pharmaceutical Tianjin longshunrong pharmaceutical factory has three production lines of liquid, tablet and granule, with 88 registered varieties. Many varieties have won many awards, among which refined Yinqiao antidote tablets have been exported to 14 countries and regions since 1958, and have been awarded the title of high-quality products in Tianjin for many times. Huoxiang Zhengqi water won the National Silver Award in 1979, and won the first prize in successive national similar varieties evaluation. Children's golden pill won the gold medal of China Women's and children's articles 40 years exposition in 1983 and 1990. In recent years, a series of new products have been developed: Jinqi Jiangtang Tablet, a pure Chinese medicine preparation for diabetes, Huangqing tablet, a necessary Chinese patent medicine for emergency treatment of urinary tract infection, and Zilongjin tablet, a Chinese medicine compound anticancer drug, which has reached the level of new drug research of FDA in the United States. Under the new development situation, Tianjin longshunrong Pharmaceutical Co., Ltd. of China New Pharmaceutical Co., Ltd. has established the enterprise survival concept of "making excellent traditional Chinese medicine and creating national quintessence and famous brand", and on the basis of honesty, it advocates the enterprise culture with "innovation" as the core. It advocates the concept of "honest management" in the sales work, the concept of "quality first" in the production work, the concept of "innovative development" in the technical work, and the concept of "people-oriented" in the human resource management work. In the past three years, the enterprise has initially become the leading enterprise in the same industry in Tianjin. In the development plan, the enterprise proposes: advocating the corporate culture with "innovation" as the core, pursuing excellence and maximizing the value of the enterprise; providing high-quality products and services, creating health for human beings and wealth for the society; being responsible for the employees to meet their life and growth needs, and realizing their material and spiritual interests; participating in social public welfare undertakings and being caring The enterprise embodies the social value of the enterprise; inherits the health medicine culture, creates the guiding ideology of "longshunrong" strong brand and establishes the market-oriented internal management mechanism, focuses on training the technical content of Zilongjin tablet and jinqijiangtang tablet, lays the foundation for Zilongjin tablet to impact the top three anti-cancer drugs of traditional Chinese Medicine, jinqijiangtang tablet to impact the first brand of traditional Chinese medicine; ensures the average staff The annual growth rate of income shall not be less than 8% and the annual accumulated training time per capita shall not be less than 96 class hours; a reasonable talent structure shall be established to provide human capital guarantee for the development of the enterprise; the differentiated development strategy shall be implemented to create the core competitiveness of the enterprise of "no one has me, and no one has me". The overall development goal of building longshunrong into a well-known enterprise in Chinese traditional medicine industry shall be strived for. The enterprise decision-makers believe that long Shunrong, who once led the revolution of Chinese traditional medicine industry, once represented Tianjin and even the level of Chinese traditional medicine industry, and left so many remarkable chapters in the history of Chinese pharmaceutical industry, is facing a historical opportunity to take off again. It has excellent products such as Zilongjin, Jinqi Jiangtang Tablet, and many employees who want to and can do things. It relies on the huge policy support of leaders at all levels for the enterprise, relies on the cultural accumulation of more than 100 years, and contains the power source of continuous innovation of the enterprise. Continuous progress and development on the basis of inheritance are the advantages of longshunrong. It is an important mission given by history to each person of longshunrong to inherit and lay the foundation for the future of longshunrong. We should stand on the height of revitalizing the quintessence of our country, promoting longshunrong to go to the world, on the realm of helping Shishou people, Ze and Sifang, and winning the hearts of the world by relying on the excellent quality of enterprises, and grasp tomorrow and win today! Longshunrong will be more magnificent in the future!

本文链接: https://www.waitui.com/brand/6a6702562.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

第一资本获批收购Discover

美国联邦储备委员会和货币监理署近日宣布,已批准第一资本金融公司(Capital One)收购发现金融服务公司(Discover Financial Services)的申请。这一交易还将使第一资本间接收购Discover Bank。此前,第一资本于2024年2月20日首次宣布与Discover达成一项最终协议。根据该协议,第一资本将通过全股票交易收购Discover,交易价值为353亿美元。(界面新闻)

34分钟前

中信证券:自主科技、受益欧洲资本开支扩张的板块等配置上将占优

中信证券研报表示,贸易战僵持阶段,超预期的刺激和基于妥协的贸易协议都很难发生;僵持阶段比的是两国的经济韧性,中国的政策选项更多、空间更大、能耗更久,对美国而言,7月前大规模的国债到期可能会是特朗普关税政策的第一个动摇点;A股也是中国贸易战中提振信心的关键环节,应充分相信国家维护资本市场稳定的决心,港股可能是阶段性的薄弱环节,但也要看到内地资金依旧整体明显低配港股。配置上,从规避不确定性的角度,自主科技、受益欧洲资本开支扩张的板块、纯内需必选消费、稳定红利以及不依赖短期业绩的题材料将占优。(证券时报)

34分钟前

盛和资源:MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响

4月20日,盛和资源(600392)发布公告称,网上出现“美国稀土生产商MP Materials(简称“MP公司”)宣布因关税停止向中国出口稀土精矿”的相关报道,公司就相关情况说明如下:2024年1月,MP公司与公司控股子公司盛和资源(新加坡)国际贸易有限公司再次续签了新的包销协议,盛和资源(新加坡)国际贸易有限公司为MP公司在中国的独家经销商;协议期限2年,到期后可延长1年;包销产品除稀土精矿外,还有其他稀土产品。截至目前,双方签署的包销协议尚在有效期内。目前因加征关税,MP公司暂时停止向中国出口稀土精矿。公司已构建了多元化的稀土原料供应渠道,四川矿、独居石以及其他国家进口矿可以作为替代供应。MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响。(新浪财经)

34分钟前

华为将发布兆瓦级超充产品

华为将于4月22日召开2025华为智能电动&智能充电网络战略与新品发布会。据了解,发布会上,华为将发布兆瓦级超充产品。根据华为此前的预告,该兆瓦级充电产品最大充电电流2400安培,最大功率1.5兆瓦,每分钟能补给20度电,15分钟可充满一辆电动重卡(约300度电池容量)。(财联社)

34分钟前

马来西亚航空考虑购买中国商飞飞机

据俄罗斯卫星社网站4月20日报道,马来西亚航空正在考虑购买中国国产飞机,中国商飞的三款商用机型C909、C919和C929都在评估范围内。马来西亚航空集团相关负责人18日对媒体表示,公司在制定未来几年的机队扩张计划,正密切评估购买中国商飞公司的飞机,双方团队已有过多轮沟通。报道称,被问及具体对C909、C919和C929中的哪款机型更感兴趣,该负责人表示,所有都在考虑之中,“我们在梳邦国际机场的运营就很适合商飞的小机型”。(界面新闻)

34分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询